CCL21 and neoplasm: In a phase I trial, the safety and specificity of immune responses to tumor antigens were evaluated following in situ vaccination with autologous DCs transduced with an adenoviral vector expressing the CCL21 gene in patients with advanced non-small cell lung carcinoma (116).